Johnson & Johnson (NYSE:JNJ) Stock Has Consensus Price Target of $274.13 According to Analysts

Johnson & Johnson (NYSE:JNJ) has been given an average rating of “Moderate Buy” by the twenty-five ratings firms that are covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $275.87.

Several equities research analysts have commented on JNJ shares. Royal Bank Of Canada upped their target price on shares of Johnson & Johnson from $265.00 to $287.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Bank of America reissued a “neutral” rating and set a $278.00 price target on shares of Johnson & Johnson in a research report on Tuesday. Freedom Capital raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 16th. Citigroup upped their price objective on shares of Johnson & Johnson from $285.00 to $298.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Finally, Johnson Rice reiterated a “buy” rating on shares of Johnson & Johnson in a report on Monday, August 3rd.

Johnson & Johnson Trading Down 2.2%

NYSE:JNJ opened at $258.81 on Tuesday. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 1-year low of $182.94 and a 1-year high of $281.07. The firm has a market capitalization of $623.70 billion, a price-to-earnings ratio of 29.99, a PEG ratio of 2.60 and a beta of 0.21. The business’s 50-day moving average price is $266.52 and its two-hundred day moving average price is $248.31.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.84 by $0.06. The company had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period in the previous year, the company earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities analysts expect that Johnson & Johnson will post 11.54 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were issued a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is 62.11%.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Bank of America raised its price target for J&J, citing growth prospects and pipeline strength. Analysts are also preparing for the company’s October 13 earnings report, with positive data for Tremfya and Carvykti supporting a generally bullish outlook. BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength
• Positive Sentiment: J&J remains attractive to income-focused investors after raising its dividend for the 64th consecutive year. Recent coverage highlights its profitability, strong operating moat and ability to offset STELARA’s loss of exclusivity and biosimilar erosion with broader revenue growth. Why Johnson & Johnson Is a Great Dividend Stock Right Now
• Positive Sentiment: New IMAAVY data in adolescent generalized myasthenia gravis showed sustained disease control, reduced corticosteroid reliance and no new safety signals, potentially strengthening J&J’s immunology portfolio. Johnson & Johnson Shares in Focus After New Adolescent gMG Data
• Neutral Sentiment: A global J&J survey found that many women do not associate menopause-related eye-health changes with menopause. The initiative may support awareness of eye-care needs, but it is not an immediate earnings catalyst. New Global Survey by Johnson & Johnson
• Negative Sentiment: Valuation remains a concern: J&J has gained roughly 43% to 52% over the past year and is near a record, while comparison coverage describes the stock as trading at a substantial premium to some alternatives. That limits the margin for error ahead of earnings.
• Negative Sentiment: Investors continue to monitor patent cliffs and biosimilar pressure, particularly following STELARA’s exclusivity loss. Dividend-focused comparisons also warn that pharmaceutical patent expirations could pressure future growth and payout confidence.

Insiders Place Their Bets

In other news, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the transaction, the executive vice president owned 23,003 shares in the company, valued at $5,779,963.81. The trade was a 50.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Jennifer Taubert sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 87,569 shares of company stock worth $23,064,544. 0.16% of the stock is owned by company insiders.

Institutional Investors Weigh In On Johnson & Johnson

Large investors have recently made changes to their positions in the stock. Outlook Capital Management LLC acquired a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $28,000. Matrix Trust Co lifted its holdings in shares of Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after purchasing an additional 54 shares in the last quarter. Montgomery Financial Services LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth about $43,000. Hyposwiss Advisors SA bought a new position in shares of Johnson & Johnson during the fourth quarter worth about $42,000. Finally, Bullseye Investment Management LLC bought a new position in shares of Johnson & Johnson during the second quarter worth about $63,000. Institutional investors own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.